X

Trial Profile

CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Non-small cell lung cancer
Focus Biomarker; Pharmacodynamics

Most Recent Events

06 Jun 2017 Status changed from not yet recruiting to recruiting, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
06 Jun 2017 Results (n=6) assessing plasma circulating tumor DNA as early biomarker (1 week) for tumor response to PD-1 therapy, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
09 Feb 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com